We are developing a robust clinical trial program to test the efficacy and safety of our investigative medicines.
Program:JANX007 (PSMA x CD3 TRACTr)
The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC.
For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449.